本帖最后由 老马 于 2012-1-13 21:20 编辑 , n& b$ @% ?/ u& c( v
/ S& q2 d; Q* U/ W# r: \ s爱必妥和阿瓦斯丁的比较! o' o) _+ S# K% D/ Y
0 g# A" x) E1 R$ }( J; U
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/1 U" n. D6 ^/ R- a
7 g: I4 n' T, f4 R( d9 o) {5 ?( t
( X! J* E, [+ I$ [2 S6 a% }- ?7 M
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
6 g( }" [! l9 ?& G# k/ g! g' c; v==================================================! j+ {" {7 R7 H
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
5 b# C# S, {* g/ P j& IPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
) |; g# j: ?+ o! n: e4 i+ }$ GResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.8 a$ |. j2 L: @7 p" t
|